Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United ...

Soleo Health has been named the exclusive in-network specialty pharmacy for Qfitlia (fitusiran) by Sanofi, the first ...

The US Food and Drug Administration granted clearances for testing instruments, a blood clot drug companion diagnostic test, and infectious disease tests, among other devices.

While the fourth quarter of 2024 continued the trend seen throughout the year of increasing momentum in FDA new drug approvals, with 16 such approvals handed out, the first quarter of 2025 has ...

The FDA approved nivolumab and ipilimumab for unresectable or metastatic hepatocellular carcinoma, a prevalent and deadly liver cancer in the U.S. CHECKMATE-9DW trial results showed improved ...

The pairing of two Bristol Myers Squibb immunotherapies is now permitted for the first-line treatment of two types of gastrointestinal cancers, after regulatory decisions handed out this past week ...

In 2025, Plozasiran (Arrowhead Pharmaceuticals), Donidalorsen (Ionis Pharmaceuticals) and Fitusiran (Sanofi/Alnylam) are expected to receive approval. All of that is being driven by increasing ...

Most of FDA reviewers are funded by industry fees, not taxpayer money. In fact, nearly half of the FDA’s $7 billion budget comes from fees paid by drug, device, and tobacco companies. About 70% ...

Guy Young, M.D. (Children’s Hospital Los Angeles) Some of the hesitancy stems from an anxiety over safety that can be traced back to the infancy of gene therapy, Lojewski said. Some of it, as ...

In a report released today, Michael Ulz from Morgan Stanley maintained a Hold rating on Alnylam Pharma (ALNY – Research Report), with a price target of $268.00. The company’s shares closed ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...